Fluoguide: Phase II readouts drawing closer - Redeye

Redeye comments on Fluoguide providing an update on its clinical trial progress. Updated timeline guidance mostly aligns with our expectations, except for a delay of phase IIa HNSCC top-line data to H2 2023e versus our previous estimate of mid-2023e. Considering promising interim data and the HNSCC delay relating to a trial expansion, our view of Fluoguide’s investment case remains essentially unchanged.

Länk till analysen i sin helhet: https://www.redeye.se/research/911547/fluoguide-phase-ii-readouts-drawing-closer?utm_source=finwire&utm_medium=RSS